LEXINGTON, Mass. / Feb 25, 2025 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York.
Panel Discussion Details:
Speaker: Robin Taylor, Ph.D., Chief Commercial Officer
Topic: “What It Takes to Move the Needle in Improving Responses in Colorectal Cancer”’
Date: 02/28/2025
Time: 1:00-2:00 p.m. ET
Location: New York City, NY
This event is for in-person participants only. Contact B. Riley for information on attending the conference.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
| Last Trade: | US$3.48 |
| Daily Change: | 0.10 2.96 |
| Daily Volume: | 812,745 |
| Market Cap: | US$82.160M |
May 15, 2025 May 12, 2025 April 28, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
